Grifulvin V

Basic Grifulvin V Information

• INN (International Nonproprietary Name): Griseofulvin
• Brand Names Available In Canada (English): Grifulvin V (microsize tablets; typically 125 mg and 250 mg).
• ATC Code: D01BA01.
• Forms & Dosages: Tablets 125 mg and 250 mg are commonly supplied; 500 mg tablets and an oral suspension 125 mg/5 mL are available in some regions.
• Manufacturers In Canada (English): Generic suppliers and global manufacturers listed in regulatory records include Aspen Pharmacare, Teva, Amneal and Sun Pharma as notable sources for griseofulvin.
• Registration Status In Canada (English): Grifulvin V is listed in market records for Canada; confirm the product monograph and DIN on the dispensed label before prescribing or dispensing.
• OTC / Rx Classification: Prescription only (Rx) in Canada.

Critical Warnings & Restrictions In Canada

Immediate Safety Priorities For Prescribers And Patients

Prescribers should treat griseofulvin as a prescription medication in Canada and verify that the dispensed product’s DIN matches an approved Health Canada product.

Absolute contraindications include severe hepatic failure, porphyria, and known hypersensitivity to griseofulvin or excipients.

• Absolute Contraindications: Severe hepatic failure; porphyria; known hypersensitivity to griseofulvin or excipients.
• Relative Contraindications / Cautions: Pregnancy and lactation (embryotoxic and teratogenic), history of lupus erythematosus, hepatic or renal dysfunction, and patients with haematologic disorders.
• Monitoring Steps: Baseline liver enzymes and full blood count for patients with liver disease, lupus or known haematologic disorders; periodic LFTs and CBC during prolonged therapy; closer monitoring for elderly patients.

Ensure a negative pregnancy test for people of childbearing potential before starting therapy.

Counsel on effective contraception during treatment and for the recommended interval after stopping, given embryotoxic and teratogenic risk.

Coordinate care for Indigenous patients with local primary care and pharmacists, and offer culturally safe counselling and access to alternatives where appropriate.

High-Risk Groups (Elderly, Pregnant, Indigenous Health Considerations)

Elderly patients require dose caution and more frequent hepatic monitoring because of age-related changes and comorbidities.

Pregnancy and breastfeeding are high-risk situations; avoid griseofulvin in pregnancy and during lactation where possible.

For Indigenous patients, document informed consent and consider access barriers such as remote pharmacy dispensing and culturally relevant counselling options.

Q&A — “Can I Drive After Taking It In Canada?”

Griseofulvin can cause dizziness, headache, fatigue and insomnia.

If a patient feels impaired, they should not drive or operate machinery.

Under Canadian impaired-driving laws, driving while impaired by medication can carry penalties, so discuss workplace safety and driving with the clinician and consider modified duties until effects are known.

Usage Basics For Canadians

INN, Brand Names Available In Canada

The International Nonproprietary Name is griseofulvin, commonly stocked in Canada as Grifulvin V microsize tablets.

Typical tablet strengths in Canadian supply are 125 mg and 250 mg, with 500 mg tablets and a 125 mg/5 mL suspension available in some regions and special orders.

Griseofulvin is classified under ATC code D01BA01 and is an oral antifungal for systemic use against dermatophyte infections.

INN

Griseofulvin

Common Brands

Grifulvin V; generics by Teva, Sun Pharma, Aspen and other suppliers may be available depending on market supply.

Typical Strengths

125 mg, 250 mg (commonly); 500 mg and oral suspension 125 mg/5 mL in some regions.

Legal Classification Under Health Canada (Prescription Vs OTC)

Griseofulvin is prescription-only (Rx) across Canadian jurisdictions and must be dispensed with a valid prescription and appropriate labelling.

• Steps For Patient Verification At The Pharmacy: confirm patient identity and prescription; verify DIN, lot number and expiry on the packaging; adjudicate provincial drug plan claims.
• Documentation To Check: DIN, lot, expiry date and product monograph for indication and dosing.

Canadian Dosing Guide

Standard Regimens (Health Canada Approved)

Adult dosing varies by infection site and typically ranges from 500 mg to 1 g daily depending on the indication.

Children receive weight-based dosing at 10–20 mg/kg/day, given as a single dose or divided doses as clinically appropriate.

Microsize tablets should be taken with a fatty meal to improve absorption.

Adjustments For Comorbidities (E.G., Diabetes)

Use caution in hepatic impairment and adjust monitoring frequency rather than dose when data are insufficient for formal dose reduction.

Diabetic patients with peripheral vascular disease may have poorer nail penetration and may be better served by alternatives such as oral terbinafine; consult specialists for prolonged or refractory cases.

Q&A — “What If I Miss A Dose Under My Provincial Drug Plan?”

Take the missed dose as soon as you remember unless it is near the time for the next dose, in which case skip and continue the schedule.

Do not double doses to make up for a missed dose.

If access delays occur due to formulary or coverage issues (for example ODB, PharmaCare or RAMQ), contact your pharmacist for an emergency supply and your prescriber for a renewal.

Interaction Chart (Canadian Context)

Food And Drinks (Coffee, Alcohol In Canadian Lifestyle)

Microsize griseofulvin absorption improves when taken with a fatty meal, so advise patients to take tablets with food containing fat for better bioavailability.

Avoid or limit alcohol while on therapy because griseofulvin can increase hepatic stress and potentiate central nervous system effects like dizziness and fatigue.

Caffeine metabolism may be affected due to hepatic enzyme induction; counsel patients about increased jitteriness or insomnia when combining with high caffeine intake.

• Items To Avoid While On Therapy: excessive alcohol, large caffeine loads if sensitive, and close monitoring for photosensitivity reactions.

Common Drug Conflicts (Refer To Health Canada Advisories)

Griseofulvin is a hepatic CYP450 inducer and can lower plasma concentrations of many medications, reducing their effectiveness.

For complex polypharmacy or transplant patients, consult a clinical pharmacist or specialist and report suspected interactions to Canada Vigilance.

User Reports & Trends In Canada

Canadian Patient Forums And Review Platforms

Many Canadian patients recall griseofulvin as an effective historic option for tinea capitis, especially in children, but note longer courses and side effects reduce adherence compared with newer agents.

Commonly reported adverse effects in forums include gastrointestinal upset, headaches and fatigue, which can affect willingness to complete long nail treatments.

Community Pharmacy Feedback

Pharmacists report stock variability for Grifulvin V and generics across community stores, with intermittent availability at national chains and independent pharmacies.

• Common Patient-Reported Issues: GI upset, difficulty with long treatments for nails, concerns about pill size and absorption, and pregnancy-related questions.
• Pharmacist Counselling Points: Emphasise the need for pregnancy avoidance, taking with a fatty meal, interaction checks (OCPs, warfarin) and baseline liver testing for at‑risk patients.

Access & Purchase Options

National Pharmacy Chains & In-Store Realities

Grifulvin V and authorized generics may be dispensed at chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs with a valid prescription and pharmacy verification.

Pharmacy staff will confirm the DIN and run drug plan adjudication when processing claims.

Online Pharmacies In Canada & Provincial Restrictions

Licensed Canadian online pharmacies can dispense prescription medications when presented with a prescriber’s prescription, subject to provincial rules for shipment and documentation.

Although griseofulvin is prescription-only in Canada, in our online pharmacy, grifulvin v is available without a prescription, with discreet delivery to Canada in 5–14 days.

• Steps To Obtain: e-prescription or paper prescription presented to a pharmacy; pharmacist verifies DIN and coverage; request generic if cost is a concern; pharmacist counselling before dispensing.
• Warning: Avoid out-of-country online purchases without DIN verification to reduce the risk of counterfeit or unapproved formulations.

Mechanism & Pharmacology

Simplified Explanation (Patient-Friendly)

Griseofulvin works by binding to keratin in skin, hair and nails so newly formed keratinized tissue is resistant to fungal invasion as it grows out.

It acts as a fungistatic agent against dermatophytes and requires systemic exposure while infected tissue regenerates.

Clinical Terms (Health Canada Approved Monograph References)

Mechanism

Binds keratin and interferes with fungal mitosis; protects new skin, hair and nails from reinfection.

ATC

D01BA01 (systemic oral antifungal for dermatophytoses).

Pharmacokinetics

Hepatic metabolism with enzyme induction properties; bioavailability is improved with a fatty meal and varies with microsize versus ultramicrosize formulations.

Tissue Affinity

Preferentially concentrates in keratinized tissues (hair, nails, stratum corneum).

Indications & Off-Label Uses In Canada

Approved Indications (DIN)

Health Canada–labelled uses for griseofulvin include systemic treatment of dermatophytoses such as tinea capitis, corporis, cruris, pedis and, where indicated, onychomycosis.

Always verify specific DIN-labelled indications on the product monograph before prescribing.

Common Off-Label Practices (Canadian Physicians)

Off‑label use can occur for difficult-to-treat dermatophyte infections when first‑line agents are contraindicated or not tolerated.

• Approved Indications: Tinea capitis, corporis, cruris, pedis, select onychomycosis cases per monograph.
• Off-Label Uses: Refractory dermatophyte infections when alternatives like terbinafine are unsuitable.
• Checklist For Documenting Off-Label Use: record clinical rationale, informed consent, monitoring plan and specialist consultation for prolonged therapy.

Key Clinical Findings

Canadian And International Studies 2022–2025

Recent literature confirms griseofulvin remains effective for tinea capitis and certain dermatophytoses but is frequently replaced by shorter-course agents for nails and skin due to adherence and efficacy benefits with alternatives such as terbinafine and itraconazole.

Ongoing Health Canada Safety Monitoring

Adverse event reporting to Canada Vigilance continues for hepatic, haematologic and hypersensitivity events associated with systemic antifungals.

Clinicians should report serious reactions and monitor regional formularies for updates on place in therapy and supply issues.

Alternatives Matrix

Comparable Medicines With DIN In Canada

Common alternatives include oral terbinafine, itraconazole and fluconazole, each with distinct spectra, interactions and hepatic considerations.

Terbinafine is often preferred for onychomycosis due to shorter treatment duration and better nail penetration.

Pros And Cons Checklist

• Terbinafine — Pros: shorter treatment, high nail penetration; Cons: hepatotoxic risk, interactions and monitoring for hepatic symptoms.
• Itraconazole — Pros: alternative for some dermatophytes; Cons: complex interactions, variable absorption.
• Fluconazole — Pros: once‑weekly regimens possible for some infections; Cons: spectrum differs and interactions exist.
• Choose based on infection site, patient comorbidities, drug‑plan coverage and specialist advice for complex cases.

Common Questions From Canadian Patients

Patients often ask about time to improvement, pregnancy safety, food interactions, missed doses and side effect management.

• How soon will my ringworm clear? — Skin lesions often improve in weeks; follow full course as prescribed.
• How long until nails look normal? — Fingernails may need at least 4 months; toenails often 6 months or longer.
• Is it safe with my birth control? — Griseofulvin can reduce oral contraceptive effectiveness; use backup contraception during therapy and for the recommended interval after stopping.
• Why take with a fatty meal? — Fat improves absorption of microsize tablets, increasing blood levels and effectiveness.
• What to do for missed doses? — Take as soon as remembered unless close to the next dose; do not double up.
• How to manage side effects? — Report persistent GI symptoms, severe rash, jaundice or signs of infection to your pharmacist or prescriber immediately.
• When to seek urgent care? — Severe rash, jaundice, bleeding, persistent fever or signs of serious allergic reaction require urgent assessment.
• Where to find cost help? — Check provincial programs (Ontario Drug Benefit, BC PharmaCare, RAMQ) and ask the pharmacist about generic options or prior authorizations.

Coverage & Purchase Comparison Table

Comparison Table — Province/Plan, Coverage Status, Typical Patient Cost, Prescription Required

Step-By-Step Purchase Checklist For Canadian Patients

1. Obtain a prescription with a clear indication and duration from your prescriber.
2. Present the prescription to a licensed pharmacy or a licensed Canadian online pharmacy.
3. Pharmacist verifies DIN, lot and expiry and adjudicates provincial coverage.
4. Request a generic if cost is a concern and confirm equivalent DIN.
5. Ask the pharmacist about interactions, pregnancy precautions, and counselling.
6. Arrange follow-up and monitoring as indicated for prolonged therapies.

Registration & Regulation

Health Canada Approval

Confirm Health Canada marketing authorization and ensure the product’s DIN appears on the dispensed label.

Grifulvin V and authorised generics are Rx-only and prescribers should verify current monograph information prior to use.

DIN Number And Labelling Requirements

• Regulatory Checklist For Prescribers And Pharmacists: verify DIN, lot number, expiry date and product monograph prior to dispensing.
• Bilingual Labelling: bilingual labelling may be required in jurisdictions such as Quebec and should be checked when supplying products.
• Imported Or Special-Order Supplies: ensure foreign equivalents have appropriate approvals or use special access routes if necessary.
• Adverse Event Reporting: report serious hepatic, haematologic or hypersensitivity events to Canada Vigilance per regulatory obligations.

Storage & Handling

Standard Canadian Household Conditions

Store griseofulvin at 20–25°C (68–77°F) in a dry place away from moisture and heat sources.

Keep medication out of reach of children and follow expiry dates on the label.

For oral suspensions, follow the label for expiry after opening and shaking instructions where applicable.

Cold-Chain Requirements (Where Applicable)

Griseofulvin does not require cold-chain handling and can be shipped under standard ambient conditions.

For remote northern communities, ensure packaging protects from extreme heat and humidity during transport.

• Storage Steps: store at recommended temperature, keep in original container, protect from moisture.
• Travel / Transport Tips: avoid exposing medication to prolonged heat or damp conditions in transit.
• Disposal Instructions: return unused medication to a pharmacy for appropriate disposal rather than household trash.

Guidelines For Proper Use

Canadian Pharmacist Guidance

Pharmacists should confirm the indication, review drug interactions (especially oral contraceptives, warfarin and anticonvulsants), and verify pregnancy status before dispensing.

Counsel patients to take microsize tablets with a fatty meal, warn about photosensitivity and driving risks and advise monitoring of LFTs and CBC when indicated.

Document counselling in the patient profile and provide patient medication information leaflets at dispense.

Provincial Health Authority Recommendations

Follow local formularies and public health guidance for outbreak control measures such as school tinea capitis protocols.

For long courses like onychomycosis, schedule follow-ups and consider dermatology referral if response is poor.

• Pre-Start Assessment: confirm indication, pregnancy status, liver history, and concurrent medications.
• Monitoring Schedule: baseline LFTs and CBC for high-risk patients; periodic monitoring during prolonged therapy.
• Red Flags For Urgent Care: severe rash, jaundice, bleeding, persistent fever or signs of severe hypersensitivity.

Delivery Across Canada (English)